期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 62, 期 8, 页码 4091-4109出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.9b00141
关键词
-
资金
- Genentech, a member of the Roche Group
Using structure- and ligand-based design principles, a novel series of piperidyl chromane arylsulfonamide Na(v)1.7 inhibitors was discovered. Early optimization focused on improvement of potency through refinement of the low energy ligand conformation and mitigation of high in vivo clearance. An in vitro hepatotoxicity hazard was identified and resolved through optimization of lipophilicity and lipophilic ligand efficiency to arrive at GNE-616 (24), a highly potent, metabolically stable, subtype selective inhibitor of Na(v)1.7. Compound 24 showed a robust PK/PD response in a Na(v)1.7-dependent mouse model, and site-directed mutagenesis was used to identify residues critical for the isoform selectivity profile of 24.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据